Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Corona Remedies Ltd

| Annual Report 2025-26

Report Source

⬤15th Jun 26

Summary : Corona Remedies Limited achieved robust growth and market outperformance in FY26, driven by strategic expansions, strong brand portfolio, and successful IPO, despite geopolitical and competitive challenges.

Annual Report Analysis & Insights

Financial Disclosures

  1. Cost of materials consumed: ₹103.51 Crores (FY26 consolidated).
  2. Purchases of Stock-in-trade: ₹150.38 Crores (FY26 consolidated).
  3. Employee benefits expense: ₹403.02 Crores (FY26 consolidated).
  4. Other expenses: ₹445.78 Crores (FY26 consolidated).
  5. Finance Costs: ₹6.97 Crores (FY26 consolidated).
  6. Trade receivables: ₹145.55 Crores (FY26 consolidated).
  7. Ageing: Not Due (₹129.04 Cr), Less than 6 Months (₹14.73 Cr), 6 Months to 1 Year (₹1.74 Cr), 1 to 2 Years (₹0.04 Cr).
  8. Revenue from Operations: ₹1,403.18 Crores (FY26 consolidated).
  9. Sale of products: ₹1,399.77 Crores (FY26 consolidated).
  10. Sale of services: ₹1.71 Crores (FY26 consolidated).
  11. Other Operating revenue: ₹1.70 Crores (FY26 consolidated).
  12. Domestic Revenue: 95.94% of total revenue.
  13. Net cash generated from operating activities: ₹229.48 Crores (FY26 consolidated).
  14. Net cash used in investing activities: (₹256.15) Crores (FY26 consolidated).
  15. Net cash used in financing activities: (₹25.28) Crores (FY26 consolidated).
  16. Cash and cash equivalents at end of year: ₹1.83 Crores (FY26 consolidated).
  17. Direct Tax Matters: ₹2.01 Crores (FY26 consolidated).
  18. Total Assets: ₹1,205.14 Crores (FY26 consolidated).
  19. Total Equity: ₹746.86 Crores (FY26 consolidated).
  20. Total Liabilities: ₹458.28 Crores (FY26 consolidated).
  21. Property, Plant and Equipment (net): ₹291.14 Crores (FY26 consolidated).
  22. Inventories: ₹125.00 Crores (FY26 consolidated).
  23. Remuneration to Key Management Personnel: ₹10.41 Crores (FY26 consolidated).
  24. Lease Rent to Relatives of KMP: ₹2.39 Crores (FY26 consolidated).
  25. Purchase of goods from La Chandra Pharmalab Private Limited: ₹4.67 Crores (FY26 consolidated).
  26. CSR expenditure to Shri Late Surajben Laxmidas Mehta Trust: ₹2.43 Crores (FY26 consolidated).
  27. Related party balances include remuneration payable to KMP (₹0.63 Cr) and advance to supplier La Chandra (₹1.68 Cr).
  28. Standalone and Consolidated financial statements presented.
  29. Standalone PAT: ₹184.85 Crores, Consolidated PAT: ₹185.12 Crores.
  30. Standalone EPS: ₹30.22, Consolidated EPS: ₹30.27.

Corporate Overview

  1. India: 96% of total revenue.
  2. Domestic Market: West Zone (45.20%), South (20.80%), North (20.03%), East (13.97%).
  3. International Presence: Expanded across 18 countries.
  4. Cost pressures and supply chain constraints due to global West Asia disturbance.
  5. Intense competition from domestic and global pharmaceutical players, leading to pricing challenges.
  6. Regulatory and compliance risks, including changes in drug pricing regulations and approval processes.
  7. Delays in receivables from distributors and customers affecting cash flow.
  8. Exposure to foreign exchange fluctuations and supply disruptions due to imported inputs and overseas business.
  9. High dependence on key therapeutic areas and brands (76% domestic sales from 32 Engine Brands).
  10. Geographical concentration in the domestic market (West Zone 45.20%).
  11. Dependence on third-party suppliers for APIs and raw materials.
  12. Reliance on external regulatory approvals and compliance.
  13. India-centric branded pharmaceutical formulation company.
  14. Develops, manufactures, and markets high-quality offerings.
  15. Focus on chronic and sub-chronic therapeutic segments.
  16. Specialist-driven model targeting specific doctors.
  17. Dual-pronged growth strategy: organic and inorganic.
  18. Confident and optimistic about strong operational performance and strategic milestones.
  19. Emphasizes superior execution, focused therapy positioning, and expanding brand portfolio.
  20. Committed to sustainable growth, value creation for stakeholders, and being a most admired company.
  21. Acknowledges challenges but highlights proactive management and resilience.
  22. B2C Company serving diverse customers including pharmacies, treatment facilities, outpatient consumers, physicians, and hospitals.
  23. Targeting Consulting Physicians, Medicine Specialists, and focused Specialists (middle-of-the-pyramid strategy).
  24. Domestic Revenue: 95.94% of total revenue.
  25. Chronic Portfolio Contribution: 71.94% of total revenue.
  26. Women's Healthcare: 27.53% of domestic sales.
  27. Cardio-Diabeto: 25.42% of domestic sales.
  28. Pain Management: 11.36% of domestic sales.
  29. Urology: 4.7x growth vs IPM, 76.49% CAGR.
  30. Bhayla, Gujarat facility: ~1.25 Billion Tablets/Capsules, 20 Million Sachets.
  31. Solan, Himachal Pradesh facility: ~403 Million Tablets/Capsules, 10 Million Liquid bottles.
  32. Upcoming Hormone Manufacturing Plant (Gujarat): 170 Million Tablets, 24 Million Softgel, 15 Million Ointments.
  33. Two DSIR-approved R&D Centres within manufacturing facilities.
  34. Commissioning of new dedicated hormone facility in the pipeline (Gujarat).
  35. Capacity enhancement through manufacturing scale-up at the Gujarat facility.
  36. Investment in La Chandra Pharmalab for backward integration in hormonal API manufacturing.
  37. Plans to launch new products within existing therapeutic areas and diversify into new therapeutic segments.
  38. Expanding international footprint in select overseas markets.

Risk Factors

  1. High dependence on key therapeutic areas.
  2. Geographical concentration in domestic market.
  3. Intense competition and pricing challenges.
  4. Regulatory and compliance risks.

Key Drivers

  1. Fastest growing company in Top 30 IPM.
  2. Strong market outperformance across key parameters.
  3. Strategic expansion into biosimilars and biologics.
  4. Successful IPO with significant oversubscription.

Auditor’s Report

  1. Unmodified opinion on standalone financial statements.
  2. Unmodified opinion on consolidated financial statements.
  3. No key audit matters to communicate in the report for standalone financial statements.
  4. No key audit matters to communicate in the report for consolidated financial statements.

Board Commentary

  1. Mr. Nirav Mehta (MD & CEO) retires by rotation and is eligible for re-appointment.
  2. Dr. Kirtikumar Mehta (Non Executive Director & Chairman) re-appointed for 5 years (April 01, 2027 to March 31, 2032).
  3. Mr. Ankur Mehta (Joint Managing Director) re-appointed.
  4. Mr. Kshitij Sheth ceased as Nominee Director w.e.f. April 23, 2025.
  5. Ms. Chetna Dharajiya appointed Company Secretary and Compliance Officer w.e.f. April 18, 2025.
  6. Final dividend of ₹10/- per equity share recommended for F.Y. 2025-26.
  7. Dividend is subject to approval by members at the Annual General Meeting.
  8. The dividend policy aims to balance shareholder payouts with business reinvestment.
  9. Brand Concentration Risk: 76% domestic sales from 32 Engine Brands.
  10. Therapy Concentration Risk: High dependence on women's healthcare, cardio-diabetes, pain management segments.
  11. Geographic Concentration Risk: West Zone contributes 45.20% of domestic sales.
  12. API and Raw Material Supply Risk: Dependence on third-party suppliers.
  13. Regulatory and Compliance Risk: Strict approvals, inspections, and price controls.
  14. No significant and material orders passed by regulators, courts, or tribunals impacting the company's going concern status.
  15. No instances of fraud reported by Statutory Auditors for F.Y. 2025-26.
  16. No benami property proceedings initiated or pending against the company.
  17. No charges or satisfaction yet to be registered with ROC beyond statutory period.
  18. No trading or investment in Crypto currency or Virtual Currency during the financial year.
  19. Estimated capital commitments remaining unexecuted: ₹11.90 Crores.
  20. Other commitment: Export obligation of ₹29.69 Crores under EPCG Scheme.

Corporate Governance

  1. Code of Conduct for Board of Directors and Senior Management.
  2. Anti-corruption and anti-bribery policy with zero-tolerance stance.
  3. Whistle Blower / Vigil Mechanism Policy for reporting concerns.
  4. Human Rights Policy explicitly incorporates Diversity, Equity, and Inclusion (DEI).
  5. Sexual Harassment Policy and Internal Complaints Committee in compliance with POSH Act.
  6. Board led by Non Executive Chairman and four Independent Directors.
  7. All Independent Directors meet the criteria of independence as per regulations.
  8. Board diversity policy adopted.
  9. Independent Directors confirmed compliance with Code of Conduct.
  10. Statutory Committees: Audit, Nomination and Remuneration, Stakeholders Relationship, Risk Management, Corporate Social Responsibility.
  11. Other Committees: Internal Committee of Directors, IPO Committee.
  12. Audit Committee comprises Mr. Ameet Desai (Chairman), Ms. Monica Kanuga, Mr. Ankur Mehta.
  13. Risk Management Committee comprises Mr. Shirish Belapure (Chairman), Mr. Bhaskar Iyer, Mr. Viral Sitwala.
  14. CSR Committee comprises Dr. Kirtikumar Mehta (Chairman), Mr. Ameet Desai, Mr. Ankur Mehta.

Management Discussion & Analysis

Future Strategy

  1. Increase market share across key therapy areas like nephrology, CNS, oncology, and dermatology.
  2. Expand Covered Market, currently representing 34.8% of the overall IPM.
  3. Offer products across the entire patient lifecycle and strengthen the women’s health segment.
  4. Launch new products within existing therapeutic areas and develop R&D-driven 'Engine Brands'.
  5. Expand international footprint in select overseas markets by leveraging hormone portfolio and R&D strengths.

Industry Overview

  1. Indian Pharmaceutical Market (IPM) recorded strong growth of 10.5% YoY in 2026, driven by chronic therapies.
  2. Global pharmaceutical market projected to grow at 8.19% CAGR from 2026 to 2034.
  3. Oncology drugs are the largest and fastest-growing therapeutic market.
  4. Indian women's health market projected to grow at 6.2% CAGR from 2026 to 2033.
  5. Government initiatives like Biopharma SHAKTI and PLI schemes support domestic manufacturing and self-reliance.

Macroeconomic Outlook

  1. Global economy faces renewed uncertainty in 2026 due to conflict and geopolitical tensions.
  2. Global growth projected to moderate to 3.1% in 2026, with downside risks from volatile geopolitical and economic landscape.
  3. Indian economy shows robust growth, supported by domestic demand, structural reforms, and infrastructure spending.
  4. India's GDP growth estimated at 7.4% in F.Y. 2025-26, projected 6.8-7.2% for FY27.

Operational Focus Areas

  1. Enhance medical representative productivity and increase products per prescriber.
  2. Intensify engagement with super-specialist doctors in metro and urban centers.
  3. Strengthen hospital and pharmacy chain distribution.
  4. Deepen presence in core therapeutic segments through targeted portfolio expansion.
  5. Harness automation, AI, and digitalization for efficiency.

Performance Drivers

  1. Broad-based market outperformance across key parameters, including volume, price, and new product growth.
  2. Strategic focus on specialist and super-specialist doctors, leading to higher prescription contribution.
  3. Successful portfolio diversification through new launches, acquisitions, and partnerships.
  4. Strong financial performance with revenue growth of 17.18%, EBITDA growth of 22.28%, and PAT growth of 33.45%.
  5. Robust manufacturing infrastructure and in-house R&D capabilities.

Risk Control Measures

  1. Diversify revenue sources through new product launches and strategic acquisitions.
  2. Expand into new therapeutic areas like nephrology, oncology, and dermatology.
  3. Strengthen backward integration and diversify sourcing to reduce supply chain risks.
  4. Maintain strong GMP compliance and regular facility upgrades.
  5. Focus on niche therapies and specialist prescribers to strengthen market position.

Critical Risks

  1. High dependence on key therapeutic areas and brands.
  2. Geographical concentration in the domestic market.
  3. Intense competition and pricing challenges.
  4. Regulatory and compliance risks.
  5. API and raw material supply chain disruptions.